Press Releases

Investors

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arrowhead Begins Dosing in Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 12, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1 clinical study of ARO-AAT, which is being developed as treatment for a rare genetic liver disease associated with alpha-1 antitrypsin
View HTML
Toggle Summary Arrowhead to Present at Barclays Global Healthcare Conference 2018
PASADENA, Calif. --(BUSINESS WIRE)--Mar. 6, 2018-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that the company will make a presentation at the following upcoming event: Barclays Global Healthcare Conference – Miami , March 13 , at 1:35 p.m.
View HTML
Toggle Summary Arrowhead Receives Regulatory Clearance to Begin Phase 1 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a first-in-human study of ARO-AAT, which
View HTML
Toggle Summary Arrowhead Pharmaceuticals Receives Orphan Drug Designation for ARO-AAT
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the United States Food and Drug Administration (FDA) has granted orphan drug designation to ARO-AAT, Arrowhead's second-generation investigational medicine for the treatment of a rare genetic liver
View HTML
Toggle Summary Arrowhead Receives Regulatory Clearance to Begin Phase 1/2 Study of ARO-HBV for Treatment of Hepatitis B
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has received approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a first-in-human study of ARO-HBV, which
View HTML
Toggle Summary Arrowhead Pharmaceuticals Reports Fiscal 2018 First Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EST PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2018 first quarter ended December 31, 2017 . The company is hosting a conference call at 4:30 p.m.
View HTML
Toggle Summary Arrowhead Pharmaceuticals to Webcast Fiscal 2018 First Quarter Results
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Friday, February 9, 2018 , at 4:30 p.m. EST to discuss its financial results for the fiscal 2018 first quarter ended December 31, 2017 .
View HTML
Toggle Summary Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $60.4 Million
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on January 22, 2018 it closed the previously announced underwritten public offering of 11,500,000 shares of its common stock, which included shares issued upon the exercise in full by the
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Pricing of Underwritten Public Offering of Common Stock
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock, offered at a price of $5.25 per share, before underwriting discounts.
View HTML
Toggle Summary Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock
PASADENA, Calif. --(BUSINESS WIRE)-- Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold
View HTML